ST7L Inhibitors
Chemical inhibitors of ST7L can involve a variety of mechanisms that interrupt cellular signaling and growth processes. Palbociclib, as a CDK4/6 inhibitor, can arrest cell cycle progression by preventing the transition from the G1 phase to the S phase. This action disrupts the typical function of ST7L in cell cycle regulation. Similarly, Trametinib can impede the function of ST7L by inhibiting the MAPK/ERK pathway, a critical cascade for cell proliferation and survival, which ST7L may influence. Further down this pathway, Vemurafenib, a selective BRAF inhibitor, can obstruct the MAPK pathway, potentially influencing ST7L's role in cell growth and division.
In addition, Sorafenib and Sunitinib can inhibit ST7L function by targeting various kinases that are essential in tumor growth, angiogenesis, and cell signaling pathways that promote cellular expansion. Sorafenib achieves this by inhibiting RAF kinases among others, while Sunitinib works as a receptor tyrosine kinase inhibitor. Erlotinib can block the function of ST7L by targeting the EGFR tyrosine kinase, which is involved in the proliferation of certain cells. Similarly, Lapatinib, which inhibits both EGFR and HER2/neu tyrosine kinases, can disrupt signaling pathways that ST7L may affect. Everolimus, an mTOR inhibitor, can halt the mTOR signaling pathway, potentially affecting ST7L's role in cell growth and proliferation.
Bortezomib, by inhibiting the proteasome, can affect ST7L's involvement in protein degradation pathways, influencing cell cycle control and survival. Dasatinib, which targets SRC family kinases and BCR-ABL, can disrupt functions of ST7L associated with cell migration, proliferation, and survival. Lastly, Gefitinib can inhibit the kinase activity of EGFR, which can impact ST7L's function related to cell proliferation and survival. Through these diverse mechanisms, these chemicals can inhibit the functional activity of ST7L, each targeting specific pathways and processes within the cell.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
ST7L is involved in cell cycle regulation, and Palbociclib, a CDK4/6 inhibitor, would inhibit ST7L function by preventing progression from G1 to S phase, which is a critical control point that ST7L may influence. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
ST7L may play a role in MAPK/ERK signaling. Trametinib, a MEK inhibitor, would inhibit ST7L function by blocking the MAPK/ERK pathway, which is downstream of RAS and is crucial for cell proliferation and survival. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
ST7L may be impacted by BRAF activity in the MAPK pathway. Vemurafenib, a BRAF inhibitor, would inhibit ST7L function by hindering the pathway that is essential for cell growth and division. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
ST7L's function could be related to angiogenesis and cell proliferation. Sorafenib, a RAF inhibitor, would inhibit ST7L function by targeting multiple kinases involved in tumor growth and angiogenesis. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
As ST7L might be involved in cell signaling pathways that facilitate growth, Sunitinib, a receptor tyrosine kinase inhibitor, would inhibit ST7L function by inhibiting signaling pathways crucial for tumor cell proliferation and angiogenesis. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $74.00 $119.00 | 33 | |
If ST7L is associated with the EGFR signaling pathway, Erlotinib, an EGFR inhibitor, would inhibit ST7L function by blocking the EGFR tyrosine kinase that is implicated in the proliferation of cancer cells. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
ST7L could be influenced by the ABL kinase activity. Imatinib, a tyrosine kinase inhibitor, would inhibit ST7L function by targeting BCR-ABL, c-KIT, and PDGFR, which are kinases involved in cell proliferation pathways. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
If ST7L interacts with the HER2/neu signaling pathway, Lapatinib, a dual EGFR and HER2/neu inhibitor, would inhibit ST7L function by blocking the tyrosine kinases essential for cancer cell growth. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
ST7L may be part of the mTOR signaling pathway. Everolimus, an mTOR inhibitor, would inhibit ST7L function by halting downstream signaling that promotes cell growth and proliferation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
If ST7L is involved in protein degradation pathways like the ubiquitin-proteasome system, Bortezomib, a proteasome inhibitor, would inhibit ST7L function by disrupting the degradation of proteins that regulate cell cycle and survival. | ||||||